Adicet Bio (ACET)
NASDAQ:ACET
Want to see ACET full AI Analyst Report?
Top Page
Adicet Bio
(NASDAQ:ACET)
Select Model
Select Model
Rating:48Neutral
Price Target:
$8.00
▼(-2.68% Downside)
Action:ReiteratedDate:04/16/26
The score is held down primarily by weak financial performance—no recent revenue, large ongoing losses, and significant cash burn despite low leverage. Technicals provide some offset with improving near-term trend signals, while valuation remains unattractive/unclear due to negative earnings and no dividend.
Positive Factors
Low leverage (debt-to-equity ~0.09)
A low debt-to-equity ratio (~0.09) indicates limited financial leverage and modest solvency risk from debt. This structural strength gives management flexibility to fund clinical programs via equity or partnerships without near-term pressure from lenders, supporting multi-quarter R&D execution.
Negative Factors
Pre-commercial with no revenue
Absence of recurring product revenue is a structural weakness: the company relies on financing, collaborations, or milestones rather than operating cash flow. Over 2–6 months this limits self‑funding capacity and increases exposure to capital market access and partner deal timing risks.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage (debt-to-equity ~0.09)
A low debt-to-equity ratio (~0.09) indicates limited financial leverage and modest solvency risk from debt. This structural strength gives management flexibility to fund clinical programs via equity or partnerships without near-term pressure from lenders, supporting multi-quarter R&D execution.
Read all positive factors
Adicet Bio (ACET) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$76.10M
Dividend YieldN/A
Average Volume (3M)141.37K
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue GrowthN/A
EPS Growth15.32%
CountryUS
Employees152
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.94
Shares Outstanding9,596,407
10 Day Avg. Volume208,867
30 Day Avg. Volume141,371
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-34.14
Enterprise Value/Ebitda-0.43
Forecast
1Y Price Target
$38.00Price Target Upside362.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-32.06
Revenue Forecast (FY)N/A
Adicet Bio Business Overview & Revenue Model
Company Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like ant...
How the Company Makes Money
Adicet Bio does not sell commercial products and, as a clinical-stage biotechnology company, it has historically generated little to no recurring revenue from product sales (null for product sales revenue). When Adicet Bio has revenue, it is prima...
Adicet Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 24.99M | 9.73M |
| Gross Profit | -6.38M | 0.00 | 0.00 | 24.99M | 9.73M |
| EBITDA | -115.73M | -110.65M | -136.53M | -64.70M | -60.41M |
| Net Income | -116.80M | -117.12M | -142.66M | -69.79M | -62.00M |
Balance Sheet | |||||
| Total Assets | 192.35M | 220.22M | 207.29M | 330.69M | 338.94M |
| Cash, Cash Equivalents and Short-Term Investments | 158.53M | 176.30M | 159.71M | 257.66M | 277.54M |
| Total Debt | 14.74M | 17.23M | 20.92M | 21.02M | 20.94M |
| Total Liabilities | 33.15M | 33.61M | 37.12M | 38.35M | 35.81M |
| Stockholders Equity | 159.21M | 186.61M | 170.18M | 292.34M | 303.13M |
Cash Flow | |||||
| Free Cash Flow | -96.98M | -93.50M | -98.18M | -61.55M | -64.10M |
| Operating Cash Flow | -95.25M | -92.38M | -93.72M | -44.77M | -51.05M |
| Investing Cash Flow | 2.39M | -119.24M | -4.46M | -16.78M | -2.80M |
| Financing Cash Flow | 75.25M | 111.31M | 236.00K | 41.51M | 242.69M |
Adicet Bio Technical Analysis
Positive
8.22
Price Trends
7.06
Positive
7.72
Positive
9.97
Negative
Market Momentum
0.15
Negative
65.00
Neutral
93.03
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACET, the sentiment is Positive. The current price of 8.22 is above the 20-day moving average (MA) of 6.91, above the 50-day MA of 7.06, and below the 200-day MA of 9.97, indicating a neutral trend. The MACD of 0.15 indicates Negative momentum. The RSI at 65.00 is Neutral, neither overbought nor oversold. The STOCH value of 93.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACET.
Adicet Bio Risk Analysis
Adicet Bio disclosed 24 risk factors in its most recent earnings report. Adicet Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Adicet Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $265.70M | -1.25 | -60.22% | ― | -100.00% | -16.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $556.49M | -0.51 | 275.30% | ― | 65.18% | 24.78% | |
48 Neutral | $76.10M | -0.50 | -82.96% | ― | ― | 15.32% | |
48 Neutral | $76.79M | -0.92 | -59.07% | ― | ― | -30.22% | |
46 Neutral | $82.37M | -5.85 | -237.54% | ― | ― | 35.75% |
* Healthcare Sector Average
ACET
Adicet Bio
7.67
-2.29
-22.95%
STRO
Sutro Biopharma
34.69
25.94
296.59%
PMVP
PMV Pharmaceuticals
1.42
0.42
42.00%
GANX
Gain Therapeutics
1.85
-0.03
-1.60%
IMMX
Immix Biopharma
8.60
6.58
325.74%
ARTV
Artiva Biotherapeutics, Inc.
9.07
6.62
270.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.